Compare Abeona Therapeutics Inc (ABEO) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hormel Foods Corp — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Hormel Foods Corp trades at $24.08 (market cap $13.37B). The key difference: Hormel Foods Corp is far larger — about 31.7× Abeona Therapeutics Inc's market cap, and Hormel Foods Corp pays a 4.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HRL | |
|---|---|---|
Market Cap | $421.19M | $13.37B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $29.25 |
52-Week Low | $4.17 | $19.74 |
Enterprise Value | $276.10M | $15.37B |
Dividend Yield | — | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Hormel Foods (HRL) trades at $24.705, down 1.26% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.40, beating expectations, but net income margin declined to 3.82% in 2025. Recent news includes the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
Outlook is mixed: strong dividend yield and consistent earnings beats support income investors, but margin pressures and bearish technicals pose near-term risks. Analyst consensus is 'Hold' with a $26.33 price target, suggesting limited upside. Macroeconomic headwinds in consumer staples may challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
